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ABSTRACT
Aims To characterise the clinical features, treatment
and outcome of children diagnosed with retinoblastoma
in Uganda.
Methods The study comprised a 6-year nationwide
enrolment with follow-up.
Results In total, 282 cases were enrolled, 26% (72) were
bilateral; 6% were lost to follow-up. Almost all diagnoses
in the ﬁrst affected eye were International Classiﬁcation of
Retinoblastoma group E or worse. Histology was available
for 92%; of those, 45%, had extraocular tumour at
diagnosis. Enucleation of the ﬁrst eye was done for 271;
94 received radiotherapy to the socket and in the last
2 years, 70 children received chemotherapy. At close of
study, 139 children had died. Survival, as determined in a
proportional hazards model adjusted for age, sex, laterality
and treatment era (pre or post introduction of
chemotherapy), varied by extent of the tumour (p<0.001);
children with only intraocular involvement were 80% less
likely to die (HR=0.21, 95% CI 0.12 to 0.35) compared
with children with extraocular involvement.
Conclusions Diagnostic delay results in relatively high
mortality among children with retinoblastoma in Uganda.
There is an urgent need for more effective treatment
modalities, particularly chemotherapy, and nationwide
efforts to encourage earlier access to medical care.
INTRODUCTION
Retinoblastoma is reported to be commoner in trop-
ical countries than in the developed world, but
population-based studies are few.1–3 Retinoblastoma
also has worse outcome with high mortality, but
follow-up in most studies is limited.4 In Uganda,
enucleation had been the only treatment available
for most cases, a minority also receiving radiother-
apy. Chemotherapy as part of initial treatment had
not been introduced when this study began. To char-
acterise cases diagnosed in Uganda, we did a 6-year
nationwide study documenting current practice,
histology and outcomes. A home visiting team
obtained near complete follow-up. It became
evident that mortality was unacceptably high and
so, in the ﬁnal 2 years of the study, with the aim of
improving survival, we introduced a programme of
neoadjuvant and adjuvant chemotherapy in one
referral centre in southwestern Uganda. Details of
this programme and its impact is the subject of
another report. Here, we describe disease character-
istics at presentation and subsequent survival of chil-
dren with retinoblastoma in Uganda.
MATERIALS AND METHODS
Starting in January 2006, ophthalmologists in
Uganda were invited to enter cases into the study
whilst retaining management; recruitment ended in
December 2011. A standard form documented
demography, clinical features, treatment and
follow-up. Staging was according to the
International Classiﬁcation of Retinoblastoma
(ICRB).5 Counsellors, using vernacular, gave infor-
mation about the disease, its treatment and the
study, and parents signed or thumb-printed they
understood and consented. A brief lifestyle and
health questionnaire was used. Data were entered
and stored on a database using EPI-INFO software
(CDC.gov). When possible, blood was taken during
anaesthesia and tumour specimens collected and
put into RNAlater (Ambion, Inc; techserv@am-
bion.com) and then transferred to the Uganda
Virus Research Institute and stored at −80°. Some
patients received radiotherapy at Mulago Hospital,
Kampala, with the country’s sole machine (cobalt
60; dose 39 Gy in 13 fractions). A few with metas-
tases were referred to the Uganda Cancer Institute
for late chemotherapy. The team responsible for
follow-up of children made extensive use of mobile
phones and home visits to track progress.
The impact of various factors on survival was ini-
tially described using Kaplan–Meier plots and life-
table methods. Further analyses using proportional
hazards regression were conducted to examine the
impact on survival of factors, such as laterality,
extent, sex and age at diagnosis. Appropriate tests
of the proportional hazards assumption were
carried out.
The study was approved by the Ethics
Committee of Mbarara University (Ruharo is
afﬁliated) and by the Uganda National Council for
Science and Technology. We certify that all applic-
able institutional and governmental regulations
concerning the ethical use of human volunteers
were followed during this research.
RESULTS
In 6 years, 282 cases were enrolled (144 (51%)
boys and 138 (49%) girls). Seventy-two (26%)
were bilateral and seven had family histories (ﬁve
families) of retinoblastoma. The median age at
diagnosis of unilateral cases was 33 months (IQR
23–48; range 4–130), and of bilateral 17.5 months
(IQR 9.5–25; range 1–72). Follow-up beyond treat-
ment was obtained for 265 of 282 children (94%),
which was to the end of study (May 2013) or
death for 257 (91%). Median follow-up for those
alive was 35 months (IQR 25–53.5; range 3–86);
for those who died, it was 7 months (IQR 5–14;
range 1–58).
Some case descriptions received from ophthal-
mologists in the nationwide study were incomplete,
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but nearly all diagnoses in the ﬁrst affected eye were group E or
already extraocular, with none below group D, except for two
with group C. All cases, except the two group C, were offered
enucleation, which was done for 271 (96%), 31 bilaterally;
others declined or died soon after. Histology was accessed for
249 of 271 operated cases (92%) and was retinoblastoma for
234. Diktyoma was suggested for 13 cases because of palisading
of cells, but clinically these were advanced retinoblastoma, so
were treated and analysed as such. No tumour was reported for
two cases after chemotherapy but they were clinically deﬁnite.
When tumour extent was reported as part of histology, 86 of
191 (45%) had optic nerve or orbital involvement.
Radiotherapy was given to sockets of 94 children after enucle-
ation (eight bilaterally) and to three intact globes. A further 18
received radiotherapy for recurrence, some following surgical
de-bulking. Late chemotherapy for metastasis was given to 19
children at the Uganda Cancer Institute. Among bilateral cases,
the stages at diagnosis of tumour in the second eye ranged from
A to E or extraocular, so treatment varied; for 20 of these, treat-
ment was either declined or the child died before it was
initiated. In the ﬁnal 2 years of the study, 70 children received
chemotherapy during initial management.
At latest follow-up, 132 children were alive. There were 125
conﬁrmed deaths and 14 presumed dead having uncontrolled
tumour at last contact, giving 139 dead in total; 11 were lost to
follow-up. Among children diagnosed before the introduction
of chemotherapy, survival at 36 months was 45% (95% CI 37%
to 53%). Table 1 shows survival of 166 children with known
outcome treated before the introduction of chemotherapy, strati-
ﬁed by tumour extent and radiotherapy. In the absence of radio-
therapy, none of the children with extraocular spread at
diagnosis survived; with radiotherapy, 34% survived. Among
those cases judged to be still intraocular at diagnosis, a quarter
died irrespective of whether they received radiotherapy. Overall,
survival, as determined in a proportional hazards model
adjusted for age, sex, laterality and treatment era (pre or post
introduction of chemotherapy), varied by extent of the tumour
(p<0.001, ﬁgure 1). Children with intraocular involvement
only, had an 80% lower risk of dying (HR=0.21, 95% CI 0.12
to 0.35) compared with children with extraocular involvement.
Macroscopic orbital tumour occurred in 72 children (27 at
enucleation, 45 at recurrence); 71 died even if given radiother-
apy and chemotherapy (67 conﬁrmed dead and 5 presumed
dead having uncontrolled tumour). The one survivor had an
early recurrence and is currently alive 33 months after diagnosis,
following chemotherapy and radiotherapy. When proptosis was
recorded, 7 of 48 were alive at last follow-up (14–43 months
after diagnosis). Thirteen had other surgery before the correct
diagnosis; survival was none of four after evisceration, one of
four after trabeculectomy, and four of ﬁve after cataract. No sur-
vivors are known of 19 having late chemotherapy for metastasis
at the Uganda Cancer Institute.
For many children included in the study, the precise mode of
death is uncertain. Orbital fungation was common without
radiotherapy but only one case was known after radiotherapy,
so it was palliative. The common sites of metastasis were skull,
or spine with paraplegia. There was one known case of hepatic
metastasis and one with local lymph node involvement. One
bilateral heritable case died with primary sarcoma of the femur.
Five children died in remission after short febrile illnesses,
apparently unrelated infections. However, the mode of death is
known for the 20 who received chemotherapy as part of initial
treatment. Fifteen had extraocular extension (seven with macro-
scopic orbital tumour) and most died with apparent intracranial
extension, following headache, convulsions or unconsciousness.
DISCUSSION
Diagnostic delay results in relatively high mortality among chil-
dren with retinoblastoma in Uganda. Nearly half of tumours
were already extraocular at the time of diagnosis; among the
94% of 282 cases in whom outcome data were available, 56%
had died after 36 months of follow-up. Indeed, prior to chemo-
therapy, even among cases with intraocular disease, mortality
was 25% with radiotherapy and 26% without it. This empha-
sises the need for additional treatment modalities (such as
Table 1 Survival of 166 children with known outcome treated
prior to the introduction of chemotherapy, by tumour extent and
radiotherapy
Tumour
extent
Intraocular Extraocular Undetermined Total
Number (%) Number (%) Number (%) Number (%)
Radiotherapy given
Alive 12 (75) 11 (34) 11 (58) 34 (51)
Died 4 (25) 21 (66) 8 (42) 33 (49)
Total 16 32 19 67
No radiotherapy
Alive 25 (74) 0 (0) 14 (52) 39 (39)
Died 9 (26) 38 (100) 13 (48) 60 (61)
Total 34 38 27 99
Total cases 50 70 46 166
Extraocular: optic nerve or sclera involved or orbital tumour present at diagnosis;
either eye if bilateral.
Intraocular: none of the above or optic disc visibly uninvolved; both eyes if bilateral.
Extent undetermined: not reported or histology not available.
Radiotherapy: to the socket after enucleation during initial treatment, excluding
recurrence.
Figure 1 Kaplan–Meier survival estimates (with 95% conﬁdence
limits) for 270 children with retinoblastoma, irrespective of treatment
given, stratiﬁed by extent of the tumour. Extraocular extent: optic nerve
or sclera involved or orbital tumour present at diagnosis; either eye if
bilateral. Intraocular extent: none of the above or optic disc visibly
uninvolved; both eyes if bilateral. Extent undetermined: histology not
reported or not accessed.
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chemotherapy) and for nationwide education campaigns with
the aim of down-staging tumours at diagnosis. Furthermore, ret-
inoblastoma masquerading as other conditions is relatively
common and a high index of suspicion should be maintained
for every child presenting with other ocular features.
Recruitment of 282 children with retinoblastoma in 6 years
conﬁrms the relatively high frequency of this malignancy in
Uganda compared with Western populations, although only an
unknown fraction of the totality of cases occurring was enrolled.
However, it remains unclear if the true incidence of disease is
higher, since the proportion of children among the population
is higher in a country such as Uganda, than for example in the
UK. Data from the population-based cancer registry, in
Kampala, indicate that incidence of retinoblastoma may be three
to four times higher than Western countries, but the ﬁgure is
based on relatively few cases and uncertainty remains.6 7 The
proportion of all cases that were bilateral was 26% and their
ages at diagnosis younger than unilateral cases, often being con-
genital; this percentage may underestimate the true ﬁgure given
the high probability of the ﬁrst tumour being fatal. Only ﬁve
families were identiﬁed with more than one child affected,
perhaps indicating that most were new mutations. It is uncertain
if this heritable portion differs from the West before it was
inﬂated there by improved survival. The aetiological signiﬁcance
of these ﬁgures is under investigation and a concurrent case–
control study will consider potential environmental causes.
The diagnosis of retinoblastoma can often be conﬁdently
made by inspection, but opacities may obscure visualisation.
Ultrasound showing tumour with calciﬁcation helps but was not
available everywhere. Bilateral cases were often congenital and
diagnosis after 6 years of age was rare, although the oldest case
was 10 years. Many presented with other features, notably
uveitis, but also cataract, buphthalmos, staphyloma, endophthal-
mitis, orbital cellulitis, hyphaema or phthisis, risking delayed
enucleation, or inappropriate surgery spreading tumour, as
occurred for 13 children. Evisceration for mistaken endophthal-
mitis was always fatal. This retinoblastoma masquerade must be
considered in every child with other diagnoses. Even with ultra-
sound, necrotic tumour causing uveitis or phthisis was difﬁcult
to detect. CT scanning and cerebrospinal ﬂuid cytology would
be ideal to detect intracranial extension but were impractical or
impossible in this setting and would not affect outcome.8 Fine
needle aspiration was not attempted in case it spread tumour
cells, though it has some advocates.
Despite some incomplete documentation, it is clear that
almost all children presented having the ﬁrst eye ﬁlled with
tumour and with no prognosis for useful vision (stage E);
around half already had extraocular extension. Many parents
had long been aware and previously refused enucleation. When
bilateral, the second eye was often earlier stage allowing possible
control, thereby saving sight. To improve outcome, earlier diag-
nosis is essential. Counselling must also aim to reduce refusal of
enucleation while still curable. Programmes have started in East
Africa alerting parents to come as soon as something white is
seen in the eye; not only would this improve survival from ret-
inoblastoma, but would also improve cataract outcome.
Histology was accessed for most (92%) leaving few clinical
diagnoses. It came from various sources (none of the patholo-
gists involved had specialist training in relation to retinoblast-
oma); some were detailed but others gave only diagnosis
without extent, hence the ‘extent undetermined’ group.
Thirteen cases were reported consistent with diktyoma because
of palisading of cells, but clinically were advanced tumours
ﬁlling the eye or uveitic, not resembling textbook ciliary body
diktyomas, so were managed as retinoblastoma. Unexpectedly
even if the nerve was reported uninvolved, the mortality was
high (25%, table 1). This may have been because of limited sam-
pling, but radiotherapy made no difference so it seems early
haematogenous metastasis may occur. For informed manage-
ment decisions, detailed histology of intraocular extent and full
nerve length are needed. A regional retinoblastoma histology
service is being established in Kenya, but permits are needed for
tissue to cross borders. Local specialist training is needed.
Follow-up was near complete with home-visiting and mobile
telephones (94%; median 35 months for survivors). This con-
trasts with other African series and allows ﬁrm conclusions
about outcome. Also in striking contrast to Western countries it
conﬁrmed high mortality.9 10 This was expected with extraocu-
lar extension, but high mortality when still intraocular (as far as
could be assessed from limited histology) was one reason for
introduction of chemotherapy.
The literature has little guidance for clinicians in Africa on
management or prognosis of retinoblastoma, though each oph-
thalmologist can expect to see several cases every year.
Preoperative assessment was often limited and enucleation con-
sidered the only option, the length and state of the optic nerve
not being noted. Adjuvant treatments may not be considered
and histology not accessed. Examination of the fellow eye for
curable tumours using indirect ophthalmoscopy with indenta-
tion may be omitted. Follow-up till at least age 7 years, watching
for reactivated disease and for siblings, is sporadic.11 This needs
to be changed but even with the best will, the prolonged man-
agement required is difﬁcult with the limited resources in
Africa, and adverse socioeconomic factors are known indicators
of poor outcome.12 Management could be better coordinated if
one or a few hospitals were designated national referral centres
for all cases.
Radiotherapy is best avoided because of facial disﬁgurement,
socket contracture and risk of later malignancy in the irradiated
ﬁeld.13 However, radiotherapy seems unavoidable with optic
nerve invasion, though it is unknown if it could be omitted if
this does not reach the resection margin. At present, Uganda has
only one radiotherapy machine (cobalt 60) serving the entire
population, so access is congested and introduction of con-
formal radiotherapy for all cancers is urgent. Many cases with
extraocular extension did not receive radiotherapy and inevit-
ably died. The study sponsored many children to access radio-
therapy, but even then, on its own it saved only 34%. With
uninvolved optic nerve, radiotherapy is unnecessary because
mortality was 25% with and 26% without this treatment; if
used, all then suffer its disadvantages. With orbital tumour, it
prevents fungation but rarely (one case out of 72) saves life.
Introduction of chemotherapy may change the indications for
use of radiotherapy.
In summary, the main obstacle to reducing mortality from ret-
inoblastoma in Uganda is delayed presentation. Once a safe and
effective treatment programme is in place, using a range of
modalities, there is an urgent need in Uganda and other coun-
tries in sub-Saharan Africa, to address diagnostic delay, with
national education campaigns encouraging people to come
forward with affected children earlier. However, there is little
point in initiating such schemes in the absence of effective
treatment.
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